Rupert Sandbrink

发表

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Christian Simader, Ursula Schmidt-Erfurth, Bernd Kirchhof, 2012, Ophthalmology.

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

Glenn J Jaffe, Christian Simader, Ursula Schmidt-Erfurth, 2014, Ophthalmology.

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

Ludwig Kappos, Xavier Montalban, Frederik Barkhof, 2009, Archives of neurology.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ludwig Kappos, Frederik Barkhof, Gilles Edan, 2014, JAMA neurology.

Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score

Jing Cui, Elizabeth W Karlson, Dana Horakova, 2009, The Lancet Neurology.

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.

Ursula Schmidt-Erfurth, Ke Yang, U. Schmidt-Erfurth, 2011, Ophthalmology.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry

Ludwig Kappos, Till Sprenger, Stefan Klöppel, 2018, Brain Imaging and Behavior.

Baseline characteristics and patient adherence in the BENEFIT study

Ludwig Kappos, Xavier Montalban, Dh Miller, 2005 .

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

Ludwig Kappos, Frederik Barkhof, Gilles Edan, 2007, Archives of neurology.

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

Ursula Schmidt-Erfurth, Quan Dong Nguyen, Oliver Zeitz, 2012, Ophthalmology.

Subtraction MR images in a multiple sclerosis multicenter clinical trial setting.

Frederik Barkhof, Hugo Vrenken, Lars Bauer, 2009, Radiology.

Prognostic relevance of antimyelin antibodies for progression to multiple sclerosis after a first demyelinating event: results from the BENEFIT study

Ludwig Kappos, Xavier Montalban, Frederik Barkhof, 2006 .

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Ludwig Kappos, Frederik Barkhof, Gilles Edan, 2007, The Lancet.